Transkaryotic Therapies Inc. said it has licensed commercialrights to the gene for low-density lipoprotein (LDL) receptorprotein discovered at the University of Texas SouthwesternMedical Center in Dallas. The license provides the Cambridge,Mass., company with worldwide, non-exclusive rights to thegene for the development of TKT's proprietary gene therapytechnology.
Financial terms were not disclosed.
(c) 1997 American Health Consultants. All rights reserved.